or Try an Advanced Search...

    Technical Analysis for ATRA - Atara Biotherapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.61 1.06% 0.01
    ATRA closed up 1.06 percent on Friday, May 17, 2024, on 1.15 times normal volume.
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ATRA trend table...
    Date Alert Name Type % Chg
    MACD Bullish Signal Line Cross Bullish 0.00%
    Wide Bands Range Expansion 0.00%
    20 DMA Resistance Bearish 1.06%
    Wide Bands Range Expansion 1.06%
    20 DMA Resistance Bearish -4.69%
    Wide Bands Range Expansion -4.69%
    Up 3 Days in a Row Strength -4.69%
    Lower Bollinger Band Walk Weakness 0.83%
    Wide Bands Range Expansion 0.83%
    Oversold Stochastic Weakness 0.83%
    Older End-of-Day Signals for ATRA ...

       Recent Intraday Alerts

    Alert Time
    10 DMA Support 1 day ago
    60 Minute Opening Range Breakdown 1 day ago
    Fell Below Previous Day's Low 1 day ago
    Down 2 % 1 day ago
    Down 1% 1 day ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Track My Stocks
    Configure default chart indicators
    ATRA Chart by TradingView
    Basic chart:

    Profile

    Atara Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of muscle wasting conditions and oncology. Its lead product candidate is PINTA 745, which is in a Phase II clinical trial for the treatment of protein-energy wasting in end-stage renal disease patients. The company is also developing STM 434, a targeted therapy for ovarian cancer and other solid tumors; and a pipeline of product candidates that are in preclinical development. Atara Biotherapeutics, Inc. was founded in 2012 and is headquartered in Brisbane, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Medicine Biopharmaceutical Clinical Medicine Solid Tumors Drugs Clinical Development Ovarian Cancer Targeted Therapy End Stage Renal Disease Renal Disease Stage Renal Disease

    Is ATRA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 11 Atara Biotherapeutics First Quarter 2024 Earnings: Beats Expectations
    May 9 Atara Biotherapeutics GAAP EPS of -$0.23 beats by $0.02, revenue of $27.36M beats by $2.67M
    May 9 Atara Biotherapeutics (ATRA) Reports Q1 Loss, Tops Revenue Estimates
    May 9 Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
    Apr 5 Atara Biotherapeutics, Inc. Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    Mar 28 Atara Biotherapeutics (ATRA) Reports Q4 Loss, Tops Revenue Estimates
    Mar 28 Atara Biotherapeutics GAAP EPS of -$0.56 misses by $0.03, revenue of $4.25M misses by $10.01M
    Mar 28 Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
    Feb 29 FDA clears Atara to begin Phase 1 study for lupus nephritis drug
    Feb 29 Atara Biotherapeutics Receives FDA Clearance of IND Application in Lupus Nephritis for ATA3219, an Allogeneic CAR T Therapy
    See more ATRA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 2.535
    52 Week Low 0.1986
    Average Volume 1,591,587
    200-Day Moving Average 0.97
    50-Day Moving Average 0.68
    20-Day Moving Average 0.64
    10-Day Moving Average 0.59
    Average True Range 0.06
    RSI (14) 45.36
    ADX 15.02
    +DI 21.26
    -DI 21.34
    Chandelier Exit (Long, 3 ATRs) 0.57
    Chandelier Exit (Short, 3 ATRs) 0.68
    Upper Bollinger Bands 0.76
    Lower Bollinger Band 0.52
    Percent B (%b) 0.37
    BandWidth 37.07
    MACD Line -0.03
    MACD Signal Line -0.03
    MACD Histogram 0.0003
    Fundamentals Value
    Market Cap 62.17 Million
    Num Shares 102 Million
    EPS -2.78
    Price-to-Earnings (P/E) Ratio -0.22
    Price-to-Sales 18.35
    Price-to-Book 1.97
    PEG Ratio 0.00
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.68
    Resistance 3 (R3) 0.68 0.66 0.67
    Resistance 2 (R2) 0.66 0.64 0.66 0.67
    Resistance 1 (R1) 0.63 0.63 0.65 0.63 0.66
    Pivot Point 0.61 0.61 0.62 0.61 0.61
    Support 1 (S1) 0.59 0.59 0.60 0.59 0.56
    Support 2 (S2) 0.56 0.58 0.56 0.55
    Support 3 (S3) 0.54 0.56 0.55
    Support 4 (S4) 0.54